论文部分内容阅读
国家“七五”重点攻关项目,治疗恶性肿瘤新药——米托蒽(MitoxantroneMx)已通过国家鉴定. 上海医药工业研究院合成的Mx,经上海市卫生局批准,于1985年10月进行临床试用,上海、北京、广州等15个城市,20家肿瘤医院或肿瘤科,临床疗效验证.三年来,临宋应用500余例,可以评价疗效的431例,其中乳腺癌94例,恶性白血病44例,恶性淋巴瘤155例,胃癌,肠癌、肝癌等消化道肿瘤112例,其他肿瘤26例。单用Mx总有效率为25.6%(CR+PR),Mx与其池抗癌药物联合化疗总有效率为62.0%。在单用Mx治疗的13种肿瘤中,有乳腺癌、白血病、恶性淋巴瘤、胃、肠癌等9种肿瘤有效。临床观察的结论是:Mx和它的广谱抗肿瘤活性一致,疗效肯定。
The national “Seventh Five-Year Plan” focuses on key projects. Mitoxantrone Mx, a new drug for the treatment of malignant tumors, has passed the national appraisal. The Mx synthesized by the Shanghai Institute of Pharmaceutical Industry was clinically tested in October 1985 with the approval of the Shanghai Municipal Health Bureau. , Shanghai, Beijing, Guangzhou and other 15 cities, 20 cancer hospitals or oncology, clinical efficacy verification. In the past three years, Lin Song applied more than 500 cases, can evaluate the efficacy of 431 cases, including 94 cases of breast cancer, 44 cases of malignant leukemia There were 155 cases of malignant lymphoma, 112 cases of gastric cancer, colon cancer, and liver cancer, and 26 cases of other tumors. The total effective rate of Mx alone was 25.6% (CR+PR). The total effective rate of Mx and its pool anticancer drug combination chemotherapy was 62.0%. Of the 13 tumors treated with Mx alone, 9 tumors such as breast cancer, leukemia, malignant lymphoma, stomach and colon cancer were effective. The clinical observation concluded that Mx is consistent with its broad-spectrum antitumor activity and its efficacy is positive.